[go: up one dir, main page]

SG10201400685SA - Use Of Eicosapentaenoic Acid Ethyl Ester For Treating Hypertriglyceridemia - Google Patents

Use Of Eicosapentaenoic Acid Ethyl Ester For Treating Hypertriglyceridemia

Info

Publication number
SG10201400685SA
SG10201400685SA SG10201400685SA SG10201400685SA SG10201400685SA SG 10201400685S A SG10201400685S A SG 10201400685SA SG 10201400685S A SG10201400685S A SG 10201400685SA SG 10201400685S A SG10201400685S A SG 10201400685SA SG 10201400685S A SG10201400685S A SG 10201400685SA
Authority
SG
Singapore
Prior art keywords
eicosapentaenoic acid
ethyl ester
acid ethyl
treating hypertriglyceridemia
treating
Prior art date
Application number
SG10201400685SA
Inventor
Mehar Manku
Ian Osterloh
Pierre Wicker
Rene Braeckman
Paresh Soni
Original Assignee
Amarin Pharmaceuticals Ie Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42102041&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201400685S(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amarin Pharmaceuticals Ie Ltd filed Critical Amarin Pharmaceuticals Ie Ltd
Publication of SG10201400685SA publication Critical patent/SG10201400685SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16Z—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS, NOT OTHERWISE PROVIDED FOR
    • G16Z99/00—Subject matter not provided for in other main groups of this subclass

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

USE OF EICOSAPENTAENOIC ACID ETHYL ESTER FOR TREATING HYPERTRIGLYCERIDEMIA Abstract 5 In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or derivative thereof. a 10 No Suitable Figure 27
SG10201400685SA 2009-02-10 2010-02-09 Use Of Eicosapentaenoic Acid Ethyl Ester For Treating Hypertriglyceridemia SG10201400685SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15129109P 2009-02-10 2009-02-10
US17375509P 2009-04-29 2009-04-29

Publications (1)

Publication Number Publication Date
SG10201400685SA true SG10201400685SA (en) 2015-01-29

Family

ID=42102041

Family Applications (3)

Application Number Title Priority Date Filing Date
SG10201610916SA SG10201610916SA (en) 2009-02-10 2010-02-09 Use of eicosapentaenoic acid ethyl ester for treating hypertriglyceridemia
SG10201400685SA SG10201400685SA (en) 2009-02-10 2010-02-09 Use Of Eicosapentaenoic Acid Ethyl Ester For Treating Hypertriglyceridemia
SG2011057353A SG173612A1 (en) 2009-02-10 2010-02-09 Use of eicosapentaenoic acid ethyl ester for treating hypertriglyceridemia

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201610916SA SG10201610916SA (en) 2009-02-10 2010-02-09 Use of eicosapentaenoic acid ethyl ester for treating hypertriglyceridemia

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG2011057353A SG173612A1 (en) 2009-02-10 2010-02-09 Use of eicosapentaenoic acid ethyl ester for treating hypertriglyceridemia

Country Status (23)

Country Link
US (29) US8293727B2 (en)
EP (5) EP3616694A1 (en)
KR (2) KR101383006B1 (en)
AU (1) AU2010213899B2 (en)
BR (1) BRPI1007518A2 (en)
CA (3) CA3089847C (en)
CY (2) CY1122629T1 (en)
DK (3) DK2596786T3 (en)
ES (3) ES2768091T3 (en)
HR (3) HRP20130811T1 (en)
HU (1) HUE048299T2 (en)
LT (2) LT2596786T (en)
MX (1) MX2011008448A (en)
NZ (1) NZ594395A (en)
PH (1) PH12015500407A1 (en)
PL (3) PL2395991T3 (en)
PT (3) PT3037089T (en)
RU (2) RU2505292C2 (en)
SG (3) SG10201610916SA (en)
SI (3) SI2395991T1 (en)
SM (3) SMT202000079T1 (en)
WO (1) WO2010093634A1 (en)
ZA (1) ZA201105612B (en)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9901809D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
US20110236476A1 (en) 2008-09-02 2011-09-29 Amarin Corporation Plc. Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
MX2011007393A (en) 2009-01-12 2011-10-06 Biokier Inc Composition and method for treatment of diabetes.
US9314444B2 (en) 2009-01-12 2016-04-19 Biokier, Inc. Composition and method for treatment of NASH
US9006288B2 (en) 2009-01-12 2015-04-14 Biokier, Inc. Composition and method for treatment of diabetes
PT3037089T (en) 2009-02-10 2020-03-04 Amarin Pharmaceuticals Ie Ltd Eicosapentaenoic acid ethyl ester for treating hypertriglyceridemia
SG10201605794PA (en) 2009-04-29 2016-09-29 Amarin Pharmaceuticals Ie Ltd Stable Pharmaceutical Composition And Methods Of Using Same
WO2010127099A2 (en) 2009-04-29 2010-11-04 Amarin Corporation Plc Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
CN108096209A (en) 2009-06-15 2018-06-01 阿马里纳制药公司 Triglycerides, composition and method without increasing LDL-C levels are reduced in the object of associated Statins therapy
WO2011038122A1 (en) * 2009-09-23 2011-03-31 Amarin Corporation Plc Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
CN102711800A (en) 2009-09-23 2012-10-03 拜奥基尔公司 Composition and method for treatment of diabetes
WO2011087981A2 (en) 2010-01-15 2011-07-21 E. I. Du Pont De Nemours And Company Clinical benefits of eicosapentaenoic acid in humans
RU2606853C2 (en) * 2010-03-04 2017-01-10 Амарин Фармасьютикалз Айрлэнд Лимитед (Апил) Compositions and methods for treating and/or preventing cardiovascular disease
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
EP2646013A4 (en) * 2010-11-29 2014-03-26 Amarin Pharma Inc LOW-ERUCATION COMPOSITION AND METHODS FOR TREATING AND / OR PREVENTING CARDIOVASCULAR DISEASE IN A SUBJECT HAVING FISH ALLERGY / HYPERSENSITIVITY
US8951514B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels
US9119826B2 (en) 2011-02-16 2015-09-01 Pivotal Therapeutics, Inc. Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels
US8715648B2 (en) 2011-02-16 2014-05-06 Pivotal Therapeutics Inc. Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics
US8952000B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events
US11291643B2 (en) * 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
EP2775837A4 (en) * 2011-11-07 2015-10-28 Amarin Pharmaceuticals Ie Ltd Methods of treating hypertriglyceridemia
PT2800563T (en) 2012-01-06 2018-11-07 Chrysalis Pharma Ag Dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
JP6307442B2 (en) * 2012-01-06 2018-04-04 アマリン ファーマシューティカルス アイルランド リミテッド Compositions and methods for reducing the level of high sensitivity (HS-CRP) in a subject
WO2014189386A2 (en) * 2012-02-14 2014-11-27 Photonz Corporation Method for supervising consumption of a medical food for prevention and/or management of a disease or condition
US20130295173A1 (en) 2012-05-07 2013-11-07 Omthera Pharmaceuticals, Inc. Compositions of statins and omega-3 fatty acids
WO2013172344A1 (en) * 2012-05-15 2013-11-21 持田製薬株式会社 Cardiovascular disease primary prevention agent for patients having high blood levels of high-sensitivity c-reactive protein
US20130324607A1 (en) * 2012-06-05 2013-12-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypercholesterolemia
CA2916208A1 (en) 2012-06-17 2013-12-27 Matinas Biopharma, Inc. Omega-3 pentaenoic acid compositions and methods of use
US20140005265A1 (en) * 2012-06-29 2014-01-02 Amarin Pharmaceuticals Ireland Limited Methods for treating hypertriglyceridemia
US20140004183A1 (en) * 2012-06-29 2014-01-02 Amarin Pharmaceuticals Ireland Limited Methods for treating cardiovascular disease in statin-tolerant subjects
SMT202500326T1 (en) 2012-06-29 2025-11-10 Amarin Pharmaceuticals Ie Ltd Eicosapentaenoic acid ethyl ester for use in reducing the risk of non-fatal stroke in a subject on statin therapy
WO2014004993A2 (en) * 2012-06-29 2014-01-03 Amarin Pharmaceuticals Ireland Limited Methods of reducing ldl-p
CA2886178C (en) * 2012-09-28 2020-12-01 Mochida Pharmaceutical Co., Ltd. Composition for reducing new-onset diabetes
US20150265566A1 (en) 2012-11-06 2015-09-24 Amarin Pharmaceuticals Ireland Limited Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
US10123986B2 (en) 2012-12-24 2018-11-13 Qualitas Health, Ltd. Eicosapentaenoic acid (EPA) formulations
US9629820B2 (en) 2012-12-24 2017-04-25 Qualitas Health, Ltd. Eicosapentaenoic acid (EPA) formulations
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US20140213648A1 (en) * 2012-12-31 2014-07-31 Amarin Pharmaceuticals Ireland Limited Methods of increasing epa blood levels
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US20140221358A1 (en) * 2013-02-06 2014-08-07 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and diazoxide and methods of use thereof
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US20140221452A1 (en) * 2013-02-06 2014-08-07 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and 5-htp and methods of use thereof
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
CA2905671A1 (en) * 2013-03-13 2014-09-18 Matinas Biopharma Inc. Omega-3 pentaenoic acid compositions and methods of use
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
KR102039522B1 (en) * 2013-06-03 2019-11-26 휴렛-팩커드 디벨롭먼트 컴퍼니, 엘.피. Method and Apparatus for recording a tag using near field communication
US20140357717A1 (en) * 2013-06-04 2014-12-04 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
JP6804823B2 (en) * 2013-10-14 2020-12-23 アリゾナ・ボード・オブ・リージェンツ・オン・ビハーフ・オブ・アリゾナ・ステイト・ユニバーシティーＡｒｉｚｏｎａ Ｂｏａｒｄ ｏｆ Ｒｅｇｅｎｔｓ ｏｎ ｂｅｈａｌｆ ｏｆ Ａｒｉｚｏｎａ Ｓｔａｔｅ Ｕｎｉｖｅｒｓｉｔｙ Platinum complex and device
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
WO2015195662A1 (en) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
US10547995B2 (en) * 2015-04-30 2020-01-28 Lg Electronics Inc. Method and device for transmitting/receiving data using Bluetooth mesh network
US10183044B2 (en) 2015-05-15 2019-01-22 P Tech, Llc Systems and methods for thrombosis prevention
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
WO2018213663A1 (en) 2017-05-19 2018-11-22 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
WO2019084681A1 (en) 2017-10-30 2019-05-09 Montreal Heart Institute Methods of treating elevated plasma cholesterol
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
EP3700518A4 (en) 2018-09-24 2020-12-16 Amarin Pharmaceuticals Ireland Limited METHODS FOR REDUCING THE RISK OF CARDIOVASCULAR EVENTS IN A SUBJECT
JP2022543136A (en) * 2019-08-05 2022-10-07 アローヘッド ファーマシューティカルズ インコーポレイテッド Methods for treatment of APOC3-related diseases and disorders
CN114980973A (en) 2019-11-12 2022-08-30 阿马里纳药物爱尔兰有限公司 Method for reducing the risk of cardiovascular events in a subject with atrial fibrillation and/or atrial flutter
EP4326244A4 (en) 2021-04-21 2025-03-19 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure

Family Cites Families (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4377526A (en) * 1981-05-15 1983-03-22 Nippon Suisan Kaisha, Ltd. Method of purifying eicosapentaenoic acid and its esters
CA1239587A (en) 1983-10-24 1988-07-26 David Rubin Combined fatty acid composition for lowering blood cholestrol and triglyceride levels
US4526902A (en) * 1983-10-24 1985-07-02 Century Laboratories, Inc. Combined fatty acid composition for treatment or prophylaxis of thrombo-embolic conditions
JPS6135356A (en) * 1984-07-27 1986-02-19 Nippon Oil & Fats Co Ltd Analyzing method of fatty acid in blood lipid
US4920098A (en) * 1986-09-17 1990-04-24 Baxter International Inc. Nutritional support or therapy for individuals at risk or under treatment for atherosclerotic vascular, cardiovascular, and/or thrombotic diseases
US5252333A (en) * 1987-04-27 1993-10-12 Scotia Holdings Plc Lithium salt-containing pharmaceutical compositions
US5198468A (en) * 1987-06-24 1993-03-30 Efamol Holdings Plc Essential fatty acid composition
US4843095A (en) 1987-08-07 1989-06-27 Century Laboratories, Inc. Free fatty acids for treatment or propyhlaxis of rheumatoid arthritis arthritis
GB8819110D0 (en) * 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
US5116871A (en) * 1988-09-13 1992-05-26 Efamol Holdings Plc Fatty acid therapy and compositions for the treatment of myalgic encephalomyelitis
GB2223943A (en) 1988-10-21 1990-04-25 Tillotts Pharma Ag Oral disage forms of omega-3 polyunsaturated acids
US4935243A (en) * 1988-12-19 1990-06-19 Pharmacaps, Inc. Chewable, edible soft gelatin capsule
JP2839276B2 (en) * 1989-01-23 1998-12-16 日本分光工業株式会社 Supercritical fluid extraction / separation method and apparatus
US5457130A (en) * 1989-03-20 1995-10-10 Cancer Research Campaign Technology Limited Eicosapentaenoic acid used to treat cachexia
GB8906369D0 (en) 1989-03-20 1989-05-04 Tisdale Michael J Eicosapentaenoic acid
CA2043615C (en) 1990-06-04 2001-08-14 Kazuhiko Hata Method of producing eicosapentaenoic acid or the ester derivative thereof
GB9012651D0 (en) * 1990-06-06 1990-07-25 Efamol Holdings Essential fatty acid treatment
JP3103588B2 (en) 1990-11-16 2000-10-30 持田製薬株式会社 Lipoprotein (a) lowering agent
SE9101642D0 (en) 1991-05-30 1991-05-30 Kabi Pharmacia Ab phospholipids
US5215630A (en) * 1991-06-04 1993-06-01 Nippon Suisan Kaisha, Ltd. Method of purifying eicosapentaenoic acid or the ester derivative thereof by fractional distillation
AU2384292A (en) * 1991-07-30 1993-03-02 North Carolina State University Method and apparatus for measuring blood lipoprotein levels by nmr spectroscopy
DE4133694C2 (en) * 1991-10-11 1993-10-07 Fresenius Ag Use of an emulsion with polyunsaturated fatty acids for i.v. administration for the treatment of skin diseases
JP3400466B2 (en) * 1991-10-28 2003-04-28 日本水産株式会社 Method for producing high-purity eicosapentaenoic acid or ester thereof
JPH0649479A (en) * 1992-07-28 1994-02-22 Maruha Corp Stabilization of omega,3-unsaturated fatty acid compound
US5888541A (en) * 1992-08-21 1999-03-30 Scotia Holdings Plc Fatty acid treatment
GB9217780D0 (en) * 1992-08-21 1992-10-07 Efamol Holdings Fatty acid treatment
GB9300125D0 (en) 1993-01-06 1993-03-03 Scotia Holdings Plc Compositions containing esters of unsaturated fatty acids
WO1994028891A1 (en) 1993-06-04 1994-12-22 Martek Biosciences Corporation Method of treating coronary vascular disease using docosahexaenoic acid
GB9403857D0 (en) * 1994-03-01 1994-04-20 Scotia Holdings Plc Fatty acid derivatives
US5760081A (en) * 1994-05-10 1998-06-02 The General Hospital Corporation Omega 3 fatty acids in the prevention of ventricular fibrillation
AU711482B2 (en) * 1994-06-28 1999-10-14 Scotia Holdings Plc Compositions for treatment of diabetic complications
IT1274734B (en) * 1994-08-25 1997-07-24 Prospa Bv PHARMACEUTICAL COMPOSITIONS CONTAINING POLYUNSATURATED FATTY ACIDS, THEIR ESTERS OR SALTS, WITH VITAMINS OR ANTIOXIDANT PROVITAMINS
MY118354A (en) * 1995-05-01 2004-10-30 Scarista Ltd 1,3-propane diol derivatives as bioactive compounds
GB9519661D0 (en) * 1995-09-27 1995-11-29 Scotia Holdings Plc Fatty acid treatment
WO1997039759A2 (en) 1996-04-24 1997-10-30 Brigham And Women's Hospital Omega-3 fatty acids and omega-3 phosphatidylcholine in the treatment of bipolar disorder
TW425285B (en) 1996-06-10 2001-03-11 Viva America Marketing Inc Fish oil and garlic nutritive supplement
US5861399A (en) * 1996-07-17 1999-01-19 Heart Care Partners Methods and compositions for the rapid and enduring relief of inadequate myocardial function
US20020055539A1 (en) * 1996-10-02 2002-05-09 Bockow Barry I. Compositions and methods for treating cardiovascular conditions
KR100657642B1 (en) 1996-10-11 2006-12-19 스카리스타 리미티드 Oil comprising eicosapentaenoic acid and/or stearidonic acid
US20010006644A1 (en) 1997-07-31 2001-07-05 David J. Bova Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night
WO1999022719A1 (en) * 1997-10-30 1999-05-14 Morishita Jintan Co., Ltd. Capsular preparation containing unsaturated fatty acid or derivative thereof and process for producing the same
JP4761093B2 (en) 1997-12-10 2011-08-31 シクロスポリン セラポイティクス リミテッド Pharmaceutical composition comprising omega-3 fatty acid oil
US20020055529A1 (en) 1998-12-02 2002-05-09 Bisgaier Charles Larry Method for treating alzheimer's disease
GB9901809D0 (en) 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
US20030104048A1 (en) * 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials
US6193999B1 (en) * 1999-03-01 2001-02-27 Banner Pharmacaps, Inc. Gum acacia substituted soft gelatin capsules
ES2304061T3 (en) * 1999-07-28 2008-09-01 Swiss Caps Rechte Und Lizenzen Ag PREPARED FOR EMPLOYMENT AS A MEDICINAL PRODUCT AND / OR FOR THE COMPLEMENTATION OF EDIBLE ITEMS.
WO2001015552A1 (en) * 1999-08-30 2001-03-08 Ocean Nutrition Canada Ltd. A nutritional supplement for lowering serum triglyceride and cholesterol levels
ATE305810T1 (en) 2000-05-22 2005-10-15 Pro Aparts Investimentos E Con PHARMACEUTICAL COMPOSITION CONTAINING FATTY ACID WHICH IS AT LEAST 80 Wt. CONTAINS EPA AND DHA
GB0016045D0 (en) 2000-06-29 2000-08-23 Laxdale Limited Therapeutic combinations of fatty acids
CZ2003390A3 (en) 2000-08-15 2004-03-17 Pfizer Products Inc. Therapeutic combination of a cetp inhibitor and atorvastatin
ITMI20010129A1 (en) 2001-01-25 2002-07-25 Pharmacia & Upjohn Spa ESSENTIAL FATTY ACIDS IN THE THERAPY OF HEART INSUFFICIENCY AND HEART FAILURE
GB0111282D0 (en) 2001-05-09 2001-06-27 Laxdale Ltd Potentiation of therapeutic effects of fatty acids
CN1268328C (en) 2001-05-30 2006-08-09 拉克斯戴尔有限公司 Coenzyme q and eicosapentaenoic acid (EPA)
ITMI20012384A1 (en) * 2001-11-12 2003-05-12 Quatex Nv USE OF POLYUNSATURATED FATTY ACIDS FOR THE PRIMARY PREVENTION OF MAJOR CARDIOVASCULAR EVENTS
ITMI20020269A1 (en) 2002-02-12 2003-08-12 Victorix Assets Ltd USE OF OMEGA-3 POLYUNSATURATED ACID ETHYL STERES IN PATIENTS WITH HEART INSUFFICIENCY
HUP0200686A2 (en) 2002-02-22 2003-09-29 EURO- "H" Beruházásszervezż és Ingatlanhasznosító Kft. Electronic apparatus and method of taking part in games for guessing series of numbers by communication device
US20030166614A1 (en) * 2002-03-01 2003-09-04 Harrison Stanley F. Method for reducing cholesterol and triglycerides
CA2390820A1 (en) * 2002-06-17 2003-12-17 St. Vincent's Hospital Sydney Limited Methods of diagnosis, prognosis and treatment of cardiovascular disease
KR100956404B1 (en) * 2002-08-20 2010-05-06 교와 가부시키가이샤 Soft Capsule
US20060289834A1 (en) * 2002-11-22 2006-12-28 Nobushige Doisaki External composition containing Unsaturated fatty acid or its salt or ester
GB0228079D0 (en) 2002-12-02 2003-01-08 Laxdale Ltd Huntington's Disease
CN1756545A (en) 2003-03-05 2006-04-05 索尔瓦药物有限公司 Use of omega-3-fatty acids in the treatment of diabetic patients
BRPI0408490A (en) 2003-03-18 2006-04-04 Novartis Ag compositions comprising fatty acids and amino acids
ITMI20032247A1 (en) 2003-11-19 2005-05-20 Tiberio Bruzzese INTERACTION OF POLAR DERIVATIVES OF COMPOUNDS INSATURATED WITH INORGANIC SUBSTRATES
WO2005063231A2 (en) * 2003-12-31 2005-07-14 Igennus Limited Formulation containing an eicosapentaenoic acid or an ester thereof and a triterpene or esther thereof
US7022713B2 (en) * 2004-02-19 2006-04-04 Kowa Co., Ltd. Hyperlipemia therapeutic agent
WO2005114190A2 (en) * 2004-05-19 2005-12-01 Ppd Biomarker Discovery Sciences, Llc Methods of identifying biomarkers
JP2007284350A (en) 2004-07-27 2007-11-01 Takeda Chem Ind Ltd Diabetes treatment
ITRM20040395A1 (en) 2004-08-03 2004-11-03 Sigma Tau Ind Farmaceuti COMPOSITION INCLUDING STATINES AND FATTY ACIDS OMEGA 3.
CA2576196A1 (en) 2004-08-06 2006-02-16 Transform Pharmaceuticals, Inc. Novel statin pharmaceutical compositions and related methods of treatment
EP1790338A4 (en) 2004-09-13 2007-12-12 Santen Pharmaceutical Co Ltd THERAPEUTIC AGENT FOR KERATOCONJUNCTIVITY TYPE DISORDER
CN1759834B (en) * 2004-09-17 2010-06-23 中国医学科学院医药生物技术研究所 Application of berberine or associated with Simvastatin in preparing product for preventing or curing disease or symptom related to blood fat
EP2156826A1 (en) 2004-09-27 2010-02-24 Sigmoid Pharma Limited Microcapsule formulations comprising two pharmaceutically active ingredients
JP5491697B2 (en) 2004-10-15 2014-05-14 フォトンズ コーポレイション リミテッド Composition comprising high level omega-3 and low level saturated fatty acids
FR2878747B1 (en) 2004-12-03 2007-03-30 Pierre Fabre Medicament Sa USE OF OMEGA-3 FATTY ACID (S) FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA CAUSED BY ANTI-RETROVIRAL TREATMENT IN HIV INFECTED PATIENTS
US20070191467A1 (en) * 2004-12-06 2007-08-16 Reliant Pharmaceutical, Inc. Statin and omega-3 fatty acids for lipid therapy
JP2008522970A (en) * 2004-12-06 2008-07-03 レリアント ファーマスーティカルズ インコーポレイテッド Omega-3 fatty acids and dyslipidemic agents for lipid therapy
US20060135610A1 (en) * 2004-12-22 2006-06-22 Bortz Jonathan D Cardiovascular compositions
GB2421909A (en) * 2004-12-23 2006-07-12 Laxdale Ltd Pharmaceutical compositions comprising EPA and methods of use
US20060189682A1 (en) * 2005-02-02 2006-08-24 Payne Joseph E Water soluble prodrugs of COX-2 inhibitors
CA2600429A1 (en) 2005-03-08 2006-09-14 Reliant Pharmaceuticals, Inc. Treatment with statin and omega-3 fatty acids and a combination product thereof
EP1790339B1 (en) 2005-07-08 2014-06-04 Mochida Pharmaceutical Co., Ltd. Composition for prevention of occurrence of cardiovascular event
RU2290185C1 (en) * 2005-07-26 2006-12-27 Дмитрий Николаевич Мясников Composition for normalization of lipid metabolism and reducing body mass and method for its preparing
US20070196465A1 (en) 2005-07-28 2007-08-23 George Bobotas Treatment with dihydropyridine calcium channel blockers and omega-3 fatty acids and a combination product thereof
ITMI20051560A1 (en) 2005-08-10 2007-02-11 Tiberio Bruzzese COMPOSITION OF N-3 FATTY ACIDS WITH HIGH CONCENTRATION OF EPA AND E-O DHA AND CONTAINING N-6 FATTY ACIDS
US20090227602A1 (en) 2005-10-28 2009-09-10 John Griffin Compositions and treatments for inhibiting kinase and/or hmg-coa reductase
US20070104779A1 (en) * 2005-11-07 2007-05-10 Rongen Roelof M Treatment with omega-3 fatty acids and products thereof
BRPI0618455A2 (en) 2005-11-11 2011-08-30 Mochida Pharm Co Ltd jelly composition
US7652068B2 (en) 2005-12-20 2010-01-26 Cenestra Llc Omega 3 fatty acid formulations
PT1800675E (en) 2005-12-23 2011-08-30 Nutricia Nv Composition comprising polyunsaturated fatty acids, proteins, manganese and/or molybden and nucleosides/nucleotides for treating dementia
CN103751781A (en) * 2006-02-07 2014-04-30 持田制药株式会社 Composition for preventing recurrence of stroke
WO2007128801A1 (en) 2006-05-08 2007-11-15 Novartis Ag Combination of organic compounds
EP2777701A1 (en) 2006-05-31 2014-09-17 Mochida Pharmaceutical Co., Ltd. Composition for preventing the occurrence of a cardiovascular event in multiple risk patient comprising the ethyl ester of all-cis-5,8,11,14,17-icosapentaenoic acid
WO2008004900A1 (en) 2006-07-05 2008-01-10 Photonz Corporation Limited Production of ultrapure epa and polar lipids from largely heterotrophic culture
WO2008012329A2 (en) * 2006-07-28 2008-01-31 V. Mane Fils Seamless capsules containing high amounts of polyunsaturated fatty acids and a flavouring component
EA018734B1 (en) 2006-10-10 2013-10-30 Релайэнт Фармасьютикалз, Инк. STATIN AND OMEGA-3 FATTY ACIDS FOR REDUCTION OF Apo-B LEVELS
US20080125490A1 (en) * 2006-11-03 2008-05-29 My Svensson Treatment and prevention of cardiovascular disease in patients with chronic kidney disease by administering Omega-3 Fatty Acids
US20080306154A1 (en) 2006-11-03 2008-12-11 My Svensson Treatment and prevention of major adverse cardiovascular events or major coronary evens by administering Omega-3 fatty acids
JP5345402B2 (en) 2007-01-17 2013-11-20 持田製薬株式会社 Composition for preventing or treating diseases related to thrombus or embolism
CA2677036A1 (en) 2007-03-06 2008-09-12 Bioriginal Food & Science Corp. Soft gelatin capsule shells containing oil soluble flavoring and methods of making the same
NZ582576A (en) 2007-06-29 2012-05-25 Takeda Pharmaceutical Seamless capsule comprising gelatin and a plasticizer
US20090182049A1 (en) 2008-01-16 2009-07-16 Joar Arild Opheim Pharmaceutical Composition and Method for Treating Hypertriglyceridemia and Hypercholesterolemia in Humans
US20110118350A1 (en) 2008-05-20 2011-05-19 Mochida Pharmaceutical Co., Ltd. Composition for preventing cardiovascular event in high-risk patient
US20110236476A1 (en) 2008-09-02 2011-09-29 Amarin Corporation Plc. Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
PT3037089T (en) * 2009-02-10 2020-03-04 Amarin Pharmaceuticals Ie Ltd Eicosapentaenoic acid ethyl ester for treating hypertriglyceridemia
SG10201605794PA (en) 2009-04-29 2016-09-29 Amarin Pharmaceuticals Ie Ltd Stable Pharmaceutical Composition And Methods Of Using Same
CN108096209A (en) * 2009-06-15 2018-06-01 阿马里纳制药公司 Triglycerides, composition and method without increasing LDL-C levels are reduced in the object of associated Statins therapy
NZ609529A (en) 2010-11-04 2015-06-26 Hoffmann La Roche A composition comprising s-[2-([[1-(2-ethylbutyl)-cyclohexyl]-carbonyl]amino)phenyl] 2-methylpropanethioate and croscarmellose sodium
US20140004183A1 (en) * 2012-06-29 2014-01-02 Amarin Pharmaceuticals Ireland Limited Methods for treating cardiovascular disease in statin-tolerant subjects

Also Published As

Publication number Publication date
EP3037089A1 (en) 2016-06-29
US8440650B1 (en) 2013-05-14
US20200246300A1 (en) 2020-08-06
KR101383006B1 (en) 2014-04-08
ZA201105612B (en) 2012-10-31
US8399446B2 (en) 2013-03-19
US20180185320A1 (en) 2018-07-05
PL2395991T3 (en) 2013-11-29
CA2751576A1 (en) 2010-08-19
US20100311834A1 (en) 2010-12-09
PT2395991E (en) 2013-09-03
RU2686315C2 (en) 2019-04-25
EP2395991B1 (en) 2013-05-29
SMT202000079T1 (en) 2020-03-13
LT2596786T (en) 2020-01-10
PH12015500407B1 (en) 2015-09-21
ES2768091T3 (en) 2020-06-19
US8426399B2 (en) 2013-04-23
US20120237594A1 (en) 2012-09-20
KR20140007973A (en) 2014-01-20
PT2596786T (en) 2020-03-04
US8518929B2 (en) 2013-08-27
PL3037089T3 (en) 2020-06-01
PL2596786T3 (en) 2020-06-01
RU2011137415A (en) 2013-03-20
EP2395991A1 (en) 2011-12-21
US20130171249A1 (en) 2013-07-04
MX2011008448A (en) 2012-02-28
US8293728B2 (en) 2012-10-23
NZ594395A (en) 2014-01-31
EP2596786A1 (en) 2013-05-29
BRPI1007518A2 (en) 2018-02-20
PH12015500407A1 (en) 2015-09-21
US20240024277A1 (en) 2024-01-25
AU2010213899A1 (en) 2011-08-25
HRP20200068T1 (en) 2020-04-03
ES2769926T3 (en) 2020-06-29
US8293727B2 (en) 2012-10-23
PT3037089T (en) 2020-03-04
DK2596786T3 (en) 2020-02-24
CA2751576C (en) 2018-07-03
CA3008079A1 (en) 2010-08-19
HRP20130811T1 (en) 2013-09-30
DK2395991T3 (en) 2013-09-02
US20130004566A1 (en) 2013-01-03
SMT201300095B (en) 2013-11-08
US20210069142A1 (en) 2021-03-11
US8546372B2 (en) 2013-10-01
SG173612A1 (en) 2011-09-29
US20210251941A1 (en) 2021-08-19
SG10201610916SA (en) 2017-02-27
US20130005809A1 (en) 2013-01-03
US8357677B1 (en) 2013-01-22
US20130164375A1 (en) 2013-06-27
EP3616694A1 (en) 2020-03-04
US20120108659A1 (en) 2012-05-03
US8377920B2 (en) 2013-02-19
US20130331447A1 (en) 2013-12-12
DK3037089T3 (en) 2020-01-20
US20130017256A1 (en) 2013-01-17
HK1165698A1 (en) 2012-10-12
US8318715B2 (en) 2012-11-27
US20120157530A1 (en) 2012-06-21
US20120156285A1 (en) 2012-06-21
US20130102674A1 (en) 2013-04-25
AU2010213899B2 (en) 2014-02-06
CA3089847C (en) 2024-04-09
ES2426132T3 (en) 2013-10-21
US20120093924A1 (en) 2012-04-19
US20110288171A1 (en) 2011-11-24
RU2019111131A (en) 2020-10-15
SI2596786T1 (en) 2020-03-31
US8431560B1 (en) 2013-04-30
US8524698B2 (en) 2013-09-03
US20130004567A1 (en) 2013-01-03
HK1226307A1 (en) 2017-09-29
US20130004568A1 (en) 2013-01-03
CA3089847A1 (en) 2010-08-19
KR20110110321A (en) 2011-10-06
SI2395991T1 (en) 2013-12-31
US8367652B2 (en) 2013-02-05
CA3008079C (en) 2020-09-22
CY1122629T1 (en) 2021-03-12
US20190038590A1 (en) 2019-02-07
US20120108660A1 (en) 2012-05-03
US8415335B2 (en) 2013-04-09
US20120108663A1 (en) 2012-05-03
US20130096197A1 (en) 2013-04-18
EP3865128A1 (en) 2021-08-18
WO2010093634A1 (en) 2010-08-19
RU2013154780A (en) 2015-06-20
SI3037089T1 (en) 2020-03-31
US8314086B2 (en) 2012-11-20
US20130171250A1 (en) 2013-07-04
LT3037089T (en) 2020-01-10
SMT202000078T1 (en) 2020-03-13
EP3037089B1 (en) 2019-11-27
US20120039997A1 (en) 2012-02-16
CY1122628T1 (en) 2021-03-12
HRP20200065T1 (en) 2020-04-03
US20210046036A1 (en) 2021-02-18
US8324195B2 (en) 2012-12-04
EP2596786B1 (en) 2019-11-27
HUE048299T2 (en) 2020-07-28
RU2505292C2 (en) 2014-01-27
US20170119722A1 (en) 2017-05-04

Similar Documents

Publication Publication Date Title
SG10201400685SA (en) Use Of Eicosapentaenoic Acid Ethyl Ester For Treating Hypertriglyceridemia
MX2022010507A (en) Methods of reducing the risk of a cardiovascular event in a subject on statin therapy.
AU2018260825A1 (en) Compositions and Methods for Lowering Levels of High-Sensitivity (hs-CRP) in a Subject
NZ618734A (en) Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas
EP3682875A3 (en) Methods of treating pediatric metabolic syndrome
MX348705B (en) Pharmaceutical compositions and related methods of delivery.
EA201270221A1 (en) TREATMENT OF CROWN DISEASE WITH LACQUINIMODE
AR075423A1 (en) PHARMACEUTICAL COMPOSITION INCLUDING AN SGLT-2 INHIBITOR, PHARMACEUTICAL FORM, PROCEDURE FOR PREPARATION, TREATMENT METHODS AND ITS USES
MY173215A (en) Acetylcysteine compositions and methods of use thereof
CY1115725T1 (en) UNIONS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF BETA-AMYLOIDIC DISEASES AND CONCLUSIONS
UA96794C2 (en) Glucocorticoides, method of use thereof, treatment method and pharmaceutical formulation based thereon
MX2010008433A (en) Use of ranolazine for the treatment of cardiovascular diseases.
MX366496B (en) Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use.
SG10201809506TA (en) Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
CY1114276T1 (en) USE OF PHYSOEXPENTOENOEIC ACID FOR HYPERTENGLERIC TREATMENT
WO2009071725A3 (en) Use of valproate for the treatment of fear and phobia in subjects with alzheimer's disease
UA53455U (en) PПaЎ±б
AR075414A1 (en) COMPOSITIONS AND METHODS FOR EXTENDED THERAPY WITH AMINOPIRIDINS
UA107787C2 (en) Method of assessment of the effectiveness of treatment s-metoprolol patients with coronary heart disease with angina and hypertension in violation of left ventricular diastolic function in "hypertrophic" type
UA27832U (en) Method for treating dystrophic and vascular diseases of retina and optic nerve